# Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

> **NCT03267654** · PHASE2 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Non-small-cell Lung Cancer

## Interventions

- **DRUG:** gefitinib combined with chemotherapy
- **DRUG:** gefitinib combined with apatinib
- **DRUG:** gefitinib single agent

## Key facts

- **NCT ID:** NCT03267654
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10-12
- **Primary completion:** 2020-10-20
- **Final completion:** 2021-12-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03267654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03267654, "Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03267654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*